Navigation Links
Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
Date:7/10/2012

IRVINE, Calif. and AMSTERDAM, July 10, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Dr. Mark Gittleman, Medical Director of Breast Care Specialists and Advanced Breast Care Imaging, has joined the company's Medical Advisory Board. The board will play a key role in advising Agendia on the clinical application of its extensive product pipeline, including its Symphony suite of tests for breast cancer and its ColoPrint test for colon cancer.

(Photo: http://photos.prnewswire.com/prnh/20120710/NY37010 )

"I have been impressed by the science and methodologies behind Agendia's product development, the conversion of their tests to an FFPE format and the numerous validation studies that have been published to date," said Dr. Gittleman. "These tests have been extremely useful in appropriately directing targeted systemic therapy for my breast cancer patients. For these reasons, I am pleased to have been asked to join Agendia's Medical Advisory Board, and I look forward to contributing and sharing new ideas to reach our common goals."

As a breast cancer specialist, Dr. Gittleman has a vested interest in new technologies that enable medical professionals to better understand the biology of breast cancer, thereby helping patients attain better outcomes through the application of validated, clinically useful technologies such as Agendia's MammaPrint, BluePrint, TargetPrint and TheraPrint gene profiling tests. He is a past president of the American Society of Breast Surgeons. Dr. Gittleman currently serves on the ASBS Coding and Reimbursement and Breast Imaging Technology committees and is a reviewer for Ultrasound and Stereotactic certification applicants.

"With his vast knowledge and experience in breast imaging and minimally invasive biopsy techniques, Dr. Gittleman brings a unique perspective to our growing Medical Advisory Board," said David Macdonald, CEO of Agendia. "As Agendia invests significantly in clinical research studies to support the use of new diagnostic tests, our Medical Advisory Board will be an integral part of our clinical trial development. We look forward to working with Dr. Gittleman in our efforts to advance the future of healthcare and bring personalized medicine to breast and colon cancer patients."

About Agendia:

Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

For more information, please visit www.agendia.com.

For further information, please contact: Post+Beam Melissa Hurley Tel: +1 646 442 2773 E-mail: hurley@postandbeam.is

 

 


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
2. Agendia Signs Contract with Blue Shield of California
3. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
4. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
5. Cepheid Welcomes Senior Vice President of Human Resources
6. Study suggests expanding the genetic alphabet may be easier than previously thought
7. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
8. Medical Marijuana Inc. Shareholder Update - PhytoSPHERE Systems, LLC
9. Medi-Solve Coatings Develops Masking Process for Medical Devices
10. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
11. The Spring 2012 MediSend Biomedical Repair Training Program™ Sends Graduating Biomedical Technicians to Hospitals Around the World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Good Start ... it has eclipsed the 130 million covered lives mark ... Shield of Texas . With newly ... Company continues to enjoy strong payor acceptance based on ... clinical programs and genetic counseling, its industry-leading customer care ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL ... live events series, “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help “no-option” ...
Breaking Biology Technology:
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
Breaking Biology News(10 mins):